These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38752352)

  • 1. Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension.
    Hoeper MM; Ewert R; Jansa P; Sirenko Y; Skride A; Balagtas C; Hackley S; Vogt S; Abreu P; Haughie S; Hassan T; Oudiz RJ
    Circulation; 2024 Jun; 149(25):1949-1959. PubMed ID: 38752352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension.
    Vizza CD; Sastry BK; Safdar Z; Harnisch L; Gao X; Zhang M; Lamba M; Jing ZC
    BMC Pulm Med; 2017 Feb; 17(1):44. PubMed ID: 28228114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
    Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
    BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study.
    Rubin LJ; Badesch DB; Fleming TR; Galiè N; Simonneau G; Ghofrani HA; Oakes M; Layton G; Serdarevic-Pehar M; McLaughlin VV; Barst RJ;
    Chest; 2011 Nov; 140(5):1274-1283. PubMed ID: 21546436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.
    McLaughlin V; Channick RN; Ghofrani HA; Lemarié JC; Naeije R; Packer M; Souza R; Tapson VF; Tolson J; Al Hiti H; Meyer G; Hoeper MM
    Eur Respir J; 2015 Aug; 46(2):405-13. PubMed ID: 26113687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension.
    Barst RJ; Beghetti M; Pulido T; Layton G; Konourina I; Zhang M; Ivy DD;
    Circulation; 2014 May; 129(19):1914-23. PubMed ID: 24637559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of high dose generic sildenafil in Thai patients with pulmonary arterial hypertension.
    Durongpisitkul K; Pornrattanarungsi S; Panjasamanvong P; Chungsomprasong P
    J Med Assoc Thai; 2011 Apr; 94(4):421-6. PubMed ID: 21591526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
    Barnes H; Brown Z; Burns A; Williams T
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
    Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost AE; Engel PJ; Kramer MR; Burgess G; Collings L; Cossons N; Sitbon O; Badesch DB;
    Ann Intern Med; 2008 Oct; 149(8):521-30. PubMed ID: 18936500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study.
    Belyavskiy E; Ovchinnikov A; Potekhina A; Ageev F; Edelmann F
    BMC Cardiovasc Disord; 2020 Sep; 20(1):408. PubMed ID: 32912157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double masked, placebo controlled trial and open label extension.
    Wirostko BM; Tressler C; Hwang LJ; Burgess G; Laties AM
    BMJ; 2012 Feb; 344():e554. PubMed ID: 22354598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.
    Badesch DB; Hill NS; Burgess G; Rubin LJ; Barst RJ; Galiè N; Simonneau G;
    J Rheumatol; 2007 Dec; 34(12):2417-22. PubMed ID: 17985403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sildenafil for adult Asian patients with pulmonary arterial hypertension: a systematic review and meta-analysis.
    Shi Q; Wang Z; Yang N; Ma Y; Chen Y; Wei H; Yao H
    Ann Palliat Med; 2022 Jan; 11(1):339-351. PubMed ID: 35144425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sildenafil in pediatric pulmonary arterial hypertension.
    Dhariwal AK; Bavdekar SB
    J Postgrad Med; 2015; 61(3):181-92. PubMed ID: 26119438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative sildenafil therapy for pulmonary hypertension in infants undergoing congenital cardiac defect closure.
    El Midany AA; Mostafa EA; Azab S; Hassan GA
    Interact Cardiovasc Thorac Surg; 2013 Dec; 17(6):963-8. PubMed ID: 23985411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.
    Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost A; Engel P; Kramer MR; Serdarevic-Pehar M; Layton GR; Sitbon O; Badesch DB;
    J Heart Lung Transplant; 2014 Jul; 33(7):689-97. PubMed ID: 24815795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
    Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
    Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.
    Behr J; Nathan SD; Harari S; Wuyts W; Kirchgaessler KU; Bengus M; Gilberg F; Wells AU
    Respir Med; 2018 May; 138():13-20. PubMed ID: 29724385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.